Are we standing on the shifting sands of post-transplant metabolic-associated steatotic liver disease?

Table 1 Metabolic dysfunction-associated steatotic liver disease definition

Components	Criteria
Evidence of hepatic steatosis	Detected by imaging or histology
Presence of ≥ 1 CMRF
Overweight or obesity	BMI ≥ 25 kg/m2 (≥ 23 kg/m2 in people of Asian ethnicity) or WC ≥ 94 cm in males and ≥ 80 cm in females
Dysglycemia or T2DM	Fasting serum glucose ≥ 5.6 mmol/L (100 mg/dL) or 2-hour post-load glucose levels ≥ 7.8 mmol/L (≥ 140 mg/dL) or HbA1c ≥ 5.7% (39 mmol/L) or T2DM or treatment for T2DM
Arterial hypertension	Blood pressure ≥ 130/85 mmHg or specific antihypertensive drug treatment
Dyslipidemia	Plasma triglycerides ≥ 1.70 mmol/L (≥ 150 mg/dL) or lipid lowering treatment or plasma HDL-cholesterol ≤ 1.0 mmol/L (≤ 40 mg/dL) for males and ≤ 1.3 mmol/L (≤ 50 mg/dL) for females or lipid lowering treatment

BMI: Body mass index; CMRF: Cardiovascular metabolic risk factor; HbA1c: Glycated hemoglobin; HDL: High-density lipoprotein; T2DM: Type 2 diabetes mellitus; WC: Waist circumference.